Pressure BioSciences Raises $1M in Private Placement | GenomeWeb

NEW YORK (GenomeWeb News) – Pressure BioSciences has raised $1 million of a targeted $1.5 million in a private placement of units consisting of convertible preferred stock and warrants to purchase common stock.

In this first tranche of the placement, Pressure Bio sold an aggregate of 4,000 units at a purchase price of $250 per unit. The investors included existing investors in the firm and members of the company's board of directors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.